Siniscalchi Antonio, De Sarro Giovambattista, Pacifici Roberta, Pisani Ermanno, Sanguigni Sandro, Gallelli Luca
Siniscalchi, MD, Pisani, Department of Neurology, "Annunziata" Hospital, Cosenza, Italy. De Sarro, Gallelli, Department of Health Science, School of Medicine, University of Catanzaro Clinical Pharmacology and Pharmacovigilance Unit, Mater Domini University Hospital, Catanzaro, Italy. Pacifici, National Centre on Addiction and Doping, Istituto Superiore di Sanita, V.le Regina Elena 299, Rome. Italy. Sanguigni, Department of Neurology, Madonna del Soccorso Hospital, S Benedetto del Tronto, Italy.
Psychopharmacol Bull. 2019 Feb 15;49(1):70-79.
Alteplase is the main pharmacological treatment available for intravenous thrombolysis in patients with acute ischemic stroke. Endovascular treatment alone or add-on to intravenous thrombolysis is a valid approach in acute ischemic stroke with cerebral large vessel disease. The most common serious adverse reaction related to alteplase is the development of spontaneous intracerebral hemorrhage and the presence of cerebral small vessel disease may increase this risk, particularly in cocaine users, even if only few data have been published on this topic. Here we reviewed in cocaine users with acute ischemic stroke the efficacy and safety of thrombolytic therapy.
阿替普酶是急性缺血性脑卒中患者静脉溶栓的主要可用药物治疗方法。单独进行血管内治疗或在静脉溶栓基础上加用血管内治疗是治疗伴有脑大动脉疾病的急性缺血性脑卒中的有效方法。与阿替普酶相关的最常见严重不良反应是自发性脑出血,而脑小血管疾病的存在可能会增加这种风险,尤其是在可卡因使用者中,尽管关于这一主题的 published 数据很少。在此,我们回顾了可卡因使用者急性缺血性脑卒中溶栓治疗的疗效和安全性。 (注:原文中“published”似有误,结合语境推测可能是“published”,若有误请根据正确内容修改译文)